This was further confirmed by PET imaging studies as co-injection of the PSMA inhibitor, 2-PMPA (0.2 mg), reduced the tumor uptake of both tracers to the background level (Figure 7 and Figure 8). Here, FOLH1 is linked to neoplasm.